INOVIQ Exosome Diagnostic Solutions

Company snapshot Precision focus Precision diagnostic and exosome solutions to improve personal use only patient outcomes Compelling data $ Financial information (ASX:IIQ) Ordinary shares² 92,018,702 Disruptive technology Deep pipeline Proprietary technology platforms driving future products for cancer and other diseases Commercial products Multi-stage pipeline including SubB2M diagnostics, exosome research tools and exosome diagnostics Partnering for growth Listed options² 52-week H/L² Share price² 2,611,349 A$0.990-0.460 A$0.60 Market capitalisation² A$55.2m Cash at bank¹ A$6.3m Major shareholders (as at 10 November 2023) Merchant Funds Mgt Pty Ltd 14.2% Moggs Creek/Lawn Views Pty Ltd 5.3% Share price performance $1.00 $0.90 High accuracy exosome isolation tools and diagnostics for breast and ovarian cancers Commercial exosome isolation tools and bladder cancer detection test Partnering with KOLs and Industry to deliver clinical and commercial outcomes 1. Cash at 30 Sep 2023 (ASX: 30 Oct 2023); 2. As at 10 Nov 2023 $0.80 $0.70 $0.60 $0.50 $0.40 Jun Jul Aug Sep Oct 0 Nov INOVIQ 3M 2M 1M

View entire presentation